News & Updates

Patients with inflammatory bowel disease (IBD) report that the COVID-19 pandemic is a “major concern” for them, reveals a study, noting that the cumulative prevalence is low in this cohort. At-risk patients must be identified and counseled individually.

The Pfizer-BNT162b2 vaccine for the coronavirus disease 2019 (COVID-19) effectively reduces the risk of serious outcomes and hospitalization in patients with inflammatory bowel diseases (IBD), though with slight variance in effectivity with respect to ongoing medications, reports a Qatar study presented at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

A recent systematic review and meta-analysis has found that more than one in five patients develop postinfection irritable bowel syndrome (PI-IBS) following Clostridioides difficile infection (CDI).

The COVID-19 pandemic has contributed to self-reported increases in psychological distress and gastrointestinal symptoms among individuals with irritable bowel syndrome (IBS) and comorbid anxiety and/or depression, reveals a study.